

Quantoom Biosciences Collaborates with Stevanato Group to Elevate mRNA production with Nfinity™ Platform

Nivelles – September 14, 2023

Quantoom Biosciences ('Quantoom') is thrilled to announce a new collaboration with [Stevanato Group](#), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life science industries, with the goal of promoting and democratizing access to cutting-edge mRNA production technologies worldwide. The focus of this collaboration lies in harnessing the potential of Quantoom's revolutionary Nfinity™ Platform, a state-of-the-art, fully automated mRNA production platform, to contribute to the betterment of global health. This collaboration brings together the innovative capabilities of both industry leaders with a shared vision to enhance global health outcomes through advanced engineering and scientific solutions.

The Nfinity™ Platform comprises multiple systems, designed with a small footprint, seamless automation, and cost-effectiveness. Tailored to cater to the burgeoning demand for DNA and mRNA manufacturing and encapsulation, these systems are synergistically integrated with custom single-use consumables and ready-to-use reagent premixes. By combining their respective expertise, Quantoom and Stevanato Group will strive to cultivate a scalable optimized technology portfolio that would enable the economical production of mRNA on a global scale, thereby advancing the treatment landscape and improving global health.

"Our journey began less than two years ago with a vision to revolutionize mRNA production, and today, I am immensely proud of the strides we've made. The collaborative efforts poured into our Nfinity™ Platform have yielded an exceptional automated mRNA production solution. The vitality of this collaboration with Stevanato Group underscores the innovative spirit that drives us. Witnessing where the company stands today is not only exciting but a testament to the dedication and ingenuity of our team, as well as the meaningful partnerships we forge."
José Castillo – Chief Executive Officer at Quantoom Biosciences.

"Stevanato Group has the potential to bring innovation to the mRNA field," says Andrea Zambon, Corporate Business Development Director at Stevanato Group. *"Our expertise and capabilities in primary packaging, equipment, and analytical services for biopharmaceutical manufacturing make Stevanato Group the natural partner for Quantoom. Together, our companies can enable customers to introduce new mRNA-based drugs into the market faster, benefiting the patients waiting for them."*

###

About Quantoom Biosciences

Quantoom Biosciences is reinventing mRNA production by developing an RNA Platform (Nfinity™) that encompasses DNA (Nplify™) and RNA (Ntensify™) manufacturing and formulation (Ncapsulate™), along with critical reagent supply, from small to larger scale, ideally for pre-clinical and clinical study or trial projects. We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology. Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem. Quantoom Biosciences is part of Univercells, a global life sciences Group with the mission of making biologics accessible to all”.

www.quantoom.com

Contact details

Quantoom Biosciences

José Castillo
Chief Executive Officer
press@quantoom.com

Univercells Media Relations

Cécile Hisette
VP Corporate Communication
c.hisette@univercells.com
+32.473.36.14.11

Disclosure Statement

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.